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Abstract 
Background: In the context of our Regional Program of Hereditary Cancer, individuals fulfilling the criteria are tested 
for germline mutations to subsequently establish the clinical management. Our standard diagnostic approach focuses 
on sequencing a few classic high-risk genes, a method that frequently renders uninformative genetic results. This 
study aims to examine the improved yield offered by an On-Demand panel.
Methods: We designed an On-Demand panel for the analysis of 35-genes associated with inherited cancer suscep-
tibility in a total of 128 cases of Hereditary Breast and Ovarian Cancer (HBOC) and Hereditary Nonpolyposis Colorectal 
Cancer (HNPCC).
Results: Eighteen deleterious mutations were detected, in both routinely (BRCA2, MLH1, MSH2, PMS2) and non-rou-
tinely (ATM, BLM, BRIP1, CHEK2, MUTYH) tested genes. The screening extended to 35 genes rendered by patients carry-
ing several- up to 6-Variants of Unknown Significance (VUS). Moreover, we confirmed the splicing disruption at RNA 
level for a not previously reported BRIP1 splicing mutation. Using an On-Demand panel, we identified 18 pathogenic 
mutation carriers, seven of which would have gone unnoticed with traditional analysis.
Conclusions: Our results reinforce the utility of NGS gene panels in the diagnostic routine to increase the perfor-
mance of genetic testing, especially in individuals from families with overlapping cancer phenotypes.
Keywords: Germline mutation, Genetic counselling, Hereditary Cancer syndrome, On-Demand gene panel, Next 
generation sequencing
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Background
Carriers of germline mutations in cancer susceptibil-
ity genes represent a small but relevant proportion of all 
cancer cases. This is because an effective clinical man-
agement can be implemented in the families when the 
genetic predisposition has been identified [1]. Tradi-
tional genetic screening is based on the analysis of clas-
sical high penetrance genes that only explain the genetic 
predisposition in a reduced number of families [2]. 
Moreover, the process is time-consuming and expen-
sive, underscoring the unquestionable need not only to 
increase the number of analyzed genes, but also to do so 
by a scalable method. In that regard, the development of 
gene cancer panels, an application of massively parallel 
sequencing technology, is replacing sequential single-
gene testing. Using gene-panels, it is possible to explore 
several genes at once, increasing the chance of finding 
the causal mutation. Moreover, gene-panels represent 
an affordable next generation sequencing (NGS) applica-





5 IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM 
U1194, Université de Montpellier, Montpellier, France
Full list of author information is available at the end of the article
Page 2 of 12Velázquez et al. J Transl Med          (2020) 18:232 
gene-panel implementation is to look into the right genes 
for the particular hereditary syndrome. To satisfy this 
demand, customized panels have started to be offered.
These customized panels are being used in a large num-
ber of diagnostic laboratories, providing the opportunity 
to discuss the implementation process and increased 
mutation yields [3–5]. In general, the cohort of cancer 
cases can meet the criteria for different syndromes due 
to the overlapping phenotypes. On a practical level, the 
panel should include the candidate genes that match with 
the phenotype of the samples. A thorough analysis of the 
results is essential for evaluating the implementation of 
these custom panels and to optimize their use [6].
We aim to incorporate the study of an On-Demand 
gene panel related to HBOC (Hereditary Breast and 
Ovarian Cancer) and HNPCC (Hereditary Non Polyposis 
Colon Cancer) in the clinical routine of one of the refer-
ence laboratories in the Hereditary Community Cancer 
Program of Castile & Leon.
Materials and methods
Patients
A total of 128 index cases were enrolled in this study. This 
group comprised 72 HBOC (58 breast cancer cases and 
14 ovarian cancer cases) and 57 HNPCC, positive for the 
Amsterdam criteria. They were selected by the Regional 
Hereditary Cancer Prevention Program of Castile & Leon 
(Spain). Ethical committee approval, informed consent, 
family history and clinical features were collected.
DNA and RNA extractions
Genomic DNA from peripheral blood was automati-
cally extracted by Roche  MagNaPure® Compact, using 
the “MagNA Pure Compact Nucleic Acid Isolation Kit 
I—Large Volume” (Roche Diagnostics, Penzberg, Ger-
many), following the manufacturer’s instructions. RNA 
was extracted from peripheral blood lymphocytes using 
the GeneMATRIX Human Blood RNA Purification Kit 
(EURx, Gdánsk, Poland).
Mutation screening
All the DNA samples were screened for germline muta-
tions using the On-Demand Research Assay on the Ion 
S5 system (both ThermoFisher Scientific, Waltham, MA, 
USA). Each DNA sample was checked for concentration 
using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific). 
The concentration of input DNA was then adjusted to 
50 pmol.
The library and template preparations were performed 
using the automated Ion Chef System, then sequenced in 
Ion S5 with Ion 520 Chip (all Thermo Fisher Scientific) 
according to the manufacturer’s instructions.
Sequencing results were aligned to the hg19 human 
reference genome and analyzed using the Ion Reporter 
Software Version 5.10 (Thermo Fisher Scientific).
The variant frequency cut-off for the detection of gene 
germline mutation was defined as 20%, as recommended 
by a previous study [7].
The On-Demand Research Assay showed 99.85% sensi-
tivity, 100% specificity, 0% false-positive rate and 99.99% 
accuracy in detecting single nucleotide variations (SNVs) 
and small deletions.
Sanger sequencing
Direct automated Sanger sequencing was used to confirm 
the results detected by massive parallel sequencing. For 
this purpose, we used the BigDye Terminator Sequenc-
ing Kit v3.1 (Applied Biosystems) on an ABI 3100 DNA 
Sequencer (four capillaries; Applied Biosystems). Co-seg-
regation studies were conducted when possible.
RT‐PCR
When Human Splicing Finder (HSF) software (http://
www.umd.be/HSF3/) predicted a splicing disruption 
caused by a mutation, we performed a cDNA-based 
analysis. To this end, RNA isolated from lymphocytes 
was reverse transcribed into cDNA using the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche), according 
to the manufacturer’s protocol. We then evaluated the 
possible impact on transcription by performing a PCR, 
subsequently separating the products in low melting 2% 
agarose gel with Red Safe™ staining. After that, the bands 
were isolated and the DNA extracted using  NucleoSpin® 
Gel and PCR Clean‐up (Macherey‐Nagel, Düren, Ger-
many) was sequenced. Oligonucleotides and PCR condi-
tions are available on request.
In‑silico analyses
Mutations with protein annotations and minor allele 
frequency (MAF) < 0.01, according to ExAC data, were 
analyzed using the Cancer Genome Interpreter (https 
://www.cance rgeno meint erpre ter.org) and the Human 
Splicing Finder TM 3.0 (HSF) and (http://www.umd.be/
HSF3). To assess the potential repercussion of the vari-
ants on the protein functionality, we used the Combined 
annotation-dependent depletion (CADD) method which 
releases scaled C-scores related to the top ranked patho-
genicity: CADD-Score-10 means you are in the top 10% 
of the disrupting mutations, CADD-Score-20, top 1%, 
CADD-Score-25, top 0.5% and CADD-Score-30, 0.1%. 
CADD integrates diverse annotations into a single score 
by contrasting variants that survived natural selection 
with simulated mutations [8].
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Variant classification
Variants were classified as deleterious if: they originated 
a premature stop codon, they were located in canoni-
cal splice sites, or there was literature evidence. The 
potential deleteriousness of the remaining variants was 
evaluated using the Combined Annotation-dependent 
Depletion (CADD) method. We considered variants with 
a CADD-score of > 20 as interesting to be considered (top 
1% of disrupting variants).
Genotype–phenotype correlations and statistical analysis
Genotype-phenotype correlations between personal/
familial data and mutation profiling of the samples were 
examined. Chi square tests were used to investigate 
the relationships between the categorical variables and 
Spearman’s Rank correlation coefficient was used to 
assess the strength of association between two variables. 
Statistical tests were carried out using the R statistical 
programming language (v3.5.1).
Results
We have integrated an On-Demand Panel comprising 35 
genes associated with cancer predisposition syndromes, 
in particular HBOC and HNPCC, into our routine 
genetic testing (Table  1). All the genes have been pre-
viously identified as cancer predisposition genes. The 
analysis with the On-Demand panel has simplified and 
standardized the laboratory workflow in a single pro-
cedure to test hereditary syndromes. The 128 samples 
included in this study were sequenced in five consecutive 
experiments.
Coverage uniformity was higher than 90% in all tested 
samples. The average value of total aligned reads was 
1,040,207 (89%), and the average percentage of target 
coverage at 50 × was 88.6%, the median region coverage 
depth being 206× (range: 29–549).
The sequencing results were then filtered during the 
bioinformatics analysis and only selected variants that 
met the quality criteria were analyzed. Sufficient cover-
age was sought to ensure that all bases within ROIs were 
covered at a minimum of 30×. The Ion reporter pipeline 
parameters were adjusted to ensure greater control over 
the variant calling quality. In a first approach, a training 
set of different mutations in high penetrance genes was 
used to evaluate the performance of the panel. All the 
variants were both correctly sequenced and annotated 
(data not shown).
A total of 18 Pathogenic or Likely Pathogenic vari-
ants (PV/LPV) were identified in 18 cancer cases (14%), 
affecting 9 different genes with a current clinical utility 
for each hereditary cancer condition (Table 2).
These alterations represented 13 Single Nucleo-
tide Variants (SNVs), 4 deletions and 1 insertion, all in 
heterozygosis, and resulted in: 7 missense variants, 5 
frameshift variants, 3 nonsense variants (resulting in pre-
mature termination codon) and 3 splicing variants (1 not 
yet reported in consulted databases). This group with PV 
comprised 6 HBOC and 12 HNPCC individuals fulfilling 
the Amsterdam criteria.
Focusing on affected genes, the most frequently 
mutated gene was MUTYH with 5 variants, 4 being 
the same monoallelic mutation p.Gly396Asp. Interest-
ingly, the MAF for this mutation in ExAc is very low in 
comparison to ours, suggesting a high frequency in our 
population. Regarding the affected carriers, breast, ovar-
ian, colon and stomach were the cancer types. The other 
MUTYH PV was p.Ala385fs in a gastric cancer case. For 
ATM, BRCA2, BRIP1, CHEK2 and MSH2, two PVs were 
found in each gene. Finally, one PV was identified in the 
following genes: BLM, MLH1 and PMS2. Both ATM 
PV (p.Ser1993Argfs and p.Arg447Ter) and one of the 
BRIP1 mutations (c.1140 + 1G > C) were found in ovarian 
Table 1 Genes included in the customized On-Demand Panel
HBOC Hereditary Breast and Ovarian Cancer, HNPCC Hereditary Non Polyposis Colon Cancer
Penetrance Syndrome Gene (reference sequence)
High HBOC BRCA1 (NM_007300.3) BRCA2(NM_000059.3)
HIgh HNPCC MLH1 (NM_000249.3) MSH2 (NM_000251.2) MSH6 (NM_000179.2)
PMS2 (NM_000535.6) EPCAM (NM_002354.2)
High Others APC (NM_000038.5) BMPR1A (NM_004329.2) CDH1 (NM_004360.4) CDK4 
(NM_000075.2) MUTYH (NM_005591.3) KRAS (NM_033360.3)
PTEN (NM_000314.4) SMAD4 (NM_005359.5) STK11 (NM_000455.4)
TP53 (NM_000546.5)
Moderate-Low Multiples ATM (NM_000051.3) ATR (NM_001184.3) BLM (NM_000057.3)
BARD1 (NM_000465.3) BRIP1 (NM_032043.2) CHEK2 (NM_007194.3)
FAM175A (NM_139076.2) NBN (NM_002485.4) MEN1 (NM_000244.3)
PALB2 (NM_024675.3) FANCM(NM_020937.3) MRE11A(NM_005591.3)
PRKAR1A (NM_212471.2) RAD50 (NM_005732.3) RAD51C (NM_058216.2)
RAD51D (NM_001142571.1) POLD1 (NM_001256849.1) POLE (NM_006231.3)
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cancer cases; BRCA2 (p.Val220fs and p.Ala938fs), CHEK2 
(c.593-1G > T and p.Thr476Met), BLM (p.Gln548Ter) 
and the other BRIP1 PV (c.206-2A > G) were identified 
in women affected by breast cancer. Interestingly, the 
p.Pro747fs PV in MLH1 was detected in a breast cancer 
patient and the p.Gly71Arg in MSH2 in a woman diag-
nosed with skin cancer. Conversely, as expected, the 
other MSH2 PV (p.Arg711Ter) and the PMS2 mutation, 
p.Ser46Ile, appeared in colon cancer cases. It is worth 
noting that the ovarian cancer patients harbouring ATM 
PV, as well as the breast cancer cases with CHEK2 PV, 
present a familial history matching both HNPCC and 
HBOC criteria.
One of the questions raised is whether, by applying an 
On-Demand panel, we enhanced the testing potential as 
compared with screening BRCA and MMR genes exclu-
sively. For this question, we estimated the productivity of 
the panel design, comparing the diagnostic yields of PV 
found in traditionally screened genes and others. Using 
this comparative analysis, we aimed to determine the 
increase in PV due to the incorporation of other genes 
different from those traditionally analyzed (BRCA genes 
and MMR genes). Furthermore, to assess the suitability 
of the panel according to the type of hereditary cancer 
syndrome, we performed the analysis for each syndrome, 
HBOC and HNPCC. The results are shown in Fig. 1.
In the case of HBOC, the PV found in genes other 
than BRCA1 and BRCA2 represented 11% versus the 3% 
corresponding to BRCA genes (in particular, all the PV 
were found only in BRCA2). Conversely, for HNPCC, the 
majority of PV still resided in the traditionally screened 
genes, representing 9% versus the 4% with other genes, in 
particular, CHEK2. If we only pay attention to PVs with a 
clinical applicability, the designed On-Demand panel was 
much more efficient in the case of HBOC than HNPCC. 
This would pose the premise of not using the same cus-
tomized panel for the two different syndromes and, 
hence, to consider that different designs were necessary.
As expected, the 35 genes panel implied the detection 
of a large range of VUS, representing more than 50% of 
the genetic results for both syndromes. In the case of 
HBOC, 29% of cases carried one VUS; 10% of cases car-
ried 2; 4% of cases 3 and 10% of cases more than 3 VUS. 
For HNPCC, 35% of cases carried one VUS; 11% of cases 
2; 9% of cases 3 and 4% of cases more than 3 VUS.
In the clinics, VUS were not representing an added 
value, yet, nonetheless, these variants could offer an 
alternative explanation for cancer genetic predisposition 
Table 2 Pathogenic variants (PV)
cDNA and Protein changes are named according to the HGVS nomenclature
Reference sequence: ATM (NM_000051.3), BLM (NM_000057.3) BRCA1 (NM_007300.3) BRCA2(NM_000059.3) BRIP1 (NM_032043.2) CHEK2 (NM_007194.3) MLH1 
(NM_000249.3) MSH2 (NM_000251.2) MSH6 (NM_000179.2) MUTYH (NM_005591.3) PMS2 (NM_000535.6)
The cancer type of the index case is indicated according to the following abbreviations: Br breast cancer, Col colon cancer, End endometrial cancer, Gas gastric cancer, 
Ov ovarian cancer, Skin skin cancer
a Not previously reported
Syndrome Cancer type Gene cDNA Protein Consequence
HNPCC Ov ATM c.5979_5983delTAAAG p.Ser1993Argfs Frameshift
HNPCC Ov ATM c.1339C > T p.Arg447Ter Nonsense
HBOC Br BLM c.1642C > T p.Gln548Ter Nonsense
HBOC Br BRCA2 c.658_659delGT p.Val220fs Frameshift
HBOC Br BRCA2 c.2808_2811delACAA p.Ala938fs Frameshift
HBOC Br BRIP1 c.206-2A > G – Splicng
HNPCC Ov BRIP1 c.1140 + 1G > Ca – Splicng
HBOC End CHEK2 c.593-1G > T – Splicng
HBOC Col CHEK2 c.1427C > T p.Thr476Met Missense
HNPCC Gas MLH1 c.2239_2240insAGC CTG ATA CTA 
TAT CCT GCAGC 
p.Pro747fs Frameshift
HNPCC Br MSH2 c.211G > C p.Gly71Arg Missense
HNPCC Br MSH2 c.2131C > T p.Arg711Ter Nonsense
HNPCC Br MUTYH c.1147delC p.Ala385fs Frameshift
HNPCC Skin MUTYH c.1187G > A p.Gly396Asp Missense
HNPCC Col MUTYH c.1187G > A p.Gly396Asp Missense
HNPCC Gas MUTYH c.1187G > A p.Gly396Asp Missense
HNPCC Col MUTYH c.1187G > A p.Gly396Asp Missense
HNPCC Col PMS2 c.137G > T p.Ser46Ile Missense
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based on the polygenic model. Besides, the large per-
centage represented by VUS indirectly reduced the total 
number of negative cases in both syndromes, HBOC and 
HNPCC.
We depicted the distribution of the PV and VUS 
along the different genes and for each syndrome. In 
the case of HBOC, a total of 71 relevant variants were 
identified; for HNPCC, 60 variants. In Fig. 2, it can be 
appreciated that ATM, BRCA2, MUTYH, POLE and 
FAM175A were frequently mutated, accumulating 58% 
of the variants in HBOC and 45% in HNPCC; for other 
genes, variant distribution was divergent. In particular, 
in a number of genes for HNPCC, a non-relevant vari-
ant was found, compromising their utility in our case 
cohort. Interestingly, several VUS and PV were iden-
tified in MUTYH in HBOC, a gene normally studied 
exclusively in the context of HNPCC.
To take advantage of the results from the NGS imple-
mentation in our diagnostic routine, we further investi-
gated the VUS with MAF < 0.01, performing an in silico 
analysis using CADD. A CADD score > 20 is indicative 
Fig. 1 Representation of the different percentages of patients defined by the different types of mutation according to the Hereditary Cancer 
Syndrome. a For HBOC, the mutation rates for patients with PV in BRCA1 and BRCA2 genes (3%) was significantly lower than the 11% represented by 
PV in ATM, BLM, BRIP1 and MUTYH genes, which were not screened routinely for HBOC. A total of 53 of the cases carried 1, 2, 3 or more (up to 6) VUS. 
In the 33% of the analyzed samples, we did not find any relevant variant (negatives); b For HNPCC, the mutation rates for patients with PV in the 
MMR genes (9%) was significantly higher than the PV identified in other different genes, which in this case only refers to CHEK2. A total of 58% of the 
cases carried 1, 2, 3 or more (up to 5) VUS. In 30% of the analyzed samples, we did not find any relevant variant
Fig. 2 Distribution of the PV and VUS along the different genes according to the Hereditary Cancer Syndrome. The bar diagram represents the 
number of variants identified in the different genes. The bars define the number of VUS detected: pink bars correspond to HBOC and blue bars to 
HNPCC. The number of PVs is indicated in the upper part of the bar for the respective gene
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of possible functional repercussions caused by the vari-
ant (Additional file 1: Table S1).
We were able to analyze the segregation of VUS in a 
limited number of individuals, from 3 families, to add 
more information concerning their possible role in the 
phenotype through an accumulative effect (Fig. 3). In the 
case of family A, four variants with conflicting interpre-
tations about pathogenicity were detected in the index 
case, a woman diagnosed with breast cancer at the age of 
62. Two out of the four variants (NBN p.Asp95Asn and 
POLE p.Lys425Arg) were also detected in her sister, who 
developed ovarian cancer. In family B, the VUS in MSH6 
p.Ser144Ile segregated with the two analyzed cases of 
breast cancer, one of them being bilateral, a hallmark of 
hereditary cancer. In family C, as the different cancer 
cases were deceased, we could only test a healthy brother 
of the index case who developed breast cancer for the 
VUS (p.Arg1436Gln in POLE and p.Pro2033Ser in ATR ); 
the two of them carried both variants.
Intriguingly, some patients accumulated several high-
CADD-score variants: 11 cases with 2 VUS, 8 cases with 
3, 3 cases with 4, 5 cases with 5 and one case carried a 
total of 6 VUS. These rare missense variants with pre-
dicted functional implications would have a summatory 
effect, according to the polygenic risk model. It is worth 
noting that, by inspecting the family cancer histories, we 
observed that index cases carrying several VUS belonged 
to families with high tumor type diversity. Figure 4 com-
piles the family history of the studied cohort and the 
information about the respective VUS, both the CADD 
score and the gene in which were found.
We explored a possible correlation between the 
genetic condition of carrying VUS (ranging from 1 to 6) 
and the ages of diagnosis of the index cases. There was 
a weak  negative correlation between the genetic condi-
tion of carrying VUS (ranging from 1 to 6) and the ages 
of diagnosis of the index cases (Spearman rho = − 0.376; 
Fig. 5). Next, we tested whether there was an association 
Fig. 3 Segregation analysis of VUS. The segregation of some VUS was evaluated in three different families. The pedigrees show the different types 
of tumor in the affected probands, represented with an inner black square, and the diagnosis and current age when available. The index case is 
marked with an arrowhead. The individuals tested for the indicated mutations are surrounded by a square. Positive results are represented by “+” 
and negative ones by “−”
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between the condition of carrying VUS and the tumor 
diversity in the family. Considering the two binary vari-
ables: “carrying two or more VUS” and “having three or 
more different tumor types inside a family”, the asso-
ciation was not statistically significant (Chi square test, 
p = 0.348). Nevertheless, when the first variable was re-
defined as ”carrying three or more VUS”, the association 
was significant (Chi square test; p = 0.045).
When visualizing the data, although it was not statis-
tically significant, we did observe a trend: cases carrying 
a higher number of VUS (starting from 4 VUS onwards) 
and belonging to a family harbouring more than 3 differ-
ent cancer types (higher tumor diversity), presented an 
earlier onset of cancer (Fig. 5).
Since splicing disruption can lead to dysfunctional 
protein products, we studied, at RNA level, those muta-
tions that affected canonical or regulatory splicing sites. 
Regarding mutations located in canonical splicing sites, 
we confirmed the splicing disruption caused by a not 
previously reported c.1140 + 1G > C BRIP1 mutation. 
In Fig. 6, we can observe the presence of aberrant tran-
scripts for the carrier of the c.1140 + 1G > C variant 
in BRIP1; while the control cDNA only presented one 
band that corresponded to the wildtype transcript and 
the carrier cDNA showed an extra band in the agarose 
gel. Sequencing of the aberrant transcript subsequently 
confirmed an exon 8 skipping for the carrier of the 
c.1140 + 1G > C BRIP1 variant.
In addition, HSF indicated that the c.4076 + 4T > G 
variant in BLM, and c.4473C > T in ATM, could poten-
tially alter the splicing. Moreover, the literature pre-
sented conflicting interpretations of pathogenicity for 
both variants. Specifically, the c.4076 + 4T > G variant 
in BLM could activate an intronic cryptic donor criti-
cal site, a new donor site. On the contrary, c.4473C > T 
in ATM could result in the breaking of an exonic 
enhancer site. We did not detect any aberrant tran-
script, either for the c.4076 + 4T > G variant in BLM or 
for c.4473C > T in ATM.
Fig. 4 Correlation between cancer history and genetic results for high CADD score variants. Representation of the personal and family history of 
the samples carrying two or more VUS with high CADD scores. For each variant, the CADD-score and the gene affected is indicated. The different 
tumor types for the index case and the family members are coded as following: Br, breast; Ov, ovarian; Col, colon; Pan, pancreas; Gas, gastric; Thy, 
thyroid; Pr, porstatic; End, endometrial; H&N, head and neck; Liv, liver; Kid, kidney; CNS, central nervous system; Skin, skin; Lun, lung and CUP, cancer 
of unknown primary origin. When multiple cancer cases in the family or several variants in the same gene existed, we used the “x” symbol to 
represent the multiplicative condition: 1x (1), 2x (2), 3x (3), etc
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In an attempt to contribute to clinical actionability, in 
particular to therapy selection, we consulted the OncoKB 
database. We were looking for a registered response to 
specific targeted drugs in relation to the mutation pro-
file of the patients. It may be considered that the ATM, 
BRCA2 and CHEK2 pathogenic mutations could be 
determining a PARP inhibitor sensitivity, as already reg-
istered. Moreover, in the case of ATM pathogenic muta-
tions, the DNA-PKc and ATR inhibitors were expected 
to be effective. According to this information, a total of 6 
patients could benefit from targeted therapy options.
Discussion
To apply successful clinical management in the context of 
hereditary cancer, defining the cause of the inherited pre-
disposition is crucial. Mutations in traditionally screened, 
high penetrance genes explain a small number of cases 
[9]; nevertheless, new strategies are needed to explain the 
predisposition that remains unsolved.
Next Generation Sequencing, in particular multi-
gene panel application, has proved to be successful in 
the context of Hereditary Cancer diagnoses [4, 10, 11]. 
The implementation of the NGS in our laboratory has 
confirmed the technique’s cost-effectiveness: the On-
Demand panel allowed us to analyze a total of 128 sam-
ples in 4 consecutive experiments (5 days per experiment, 
including bioinformatic analysis), corroborating the scal-
ability and reducing the turnaround time enormously 
[12]. In addition, using targeted sequencing, we ensured 
enough coverage in the regions of interest, guaranteeing 
a robust variant calling [13].
In our study, more than 50% of the samples carried one 
or more VUS, followed by more than 30% in non-inform-
ative cases and 14% with a PV, rates similar to other 
groups using NGS multi-gene panels [4, 14].
Focusing on PV, the genetic screening has a direct 
impact on the patients; once the genetic risk is identified, 
preventive measures and management could be offered 
[15]. Although the clinical actionability is limited by the 
reduced number of guidelines [16, 17], genetic counsel-
ling is possible for most of the PVs identified [18, 19].
One of the questions raised is whether, by applying 
the On-Demand panel, we enhanced the testing poten-
tial not only detecting pathogenic mutations in BRCA 
and MMR genes, but also in other genes not tradition-
ally screened. In that regard, the On-Demand Panel 
allowed us to detect PV in 10 cases that had gone unno-
ticed with the traditional screening of the classical high 
penetrance BRCAs and MMR genes. In particular, this 
increased ratio of PV due to the On-Demand panel 
was more evident for HBOC (11%), as compared to the 
modest increased yield (3%) of the extended analysis in 
HNPCC. This poses the premise that a particular design, 
based on the clinical phenotype of the cases, would be 
needed. In this regard, laboratories differed in their opin-
ions of whether phenotypic overlap warrants offering 
pan-cancer panels only versus cancer specific panels [20]. 
One conservative but convenient strategy would seem to 
be the use of phenotype-driven panels with opportunis-
tic testing of the traditional, high penetrance BRCA and 
MMR genes [6]. In spite of the optimizations that need to 
be carried out, the On-Demand panel application led to 
reports of mutations in moderate penetrance genes that 
would otherwise have gone undetected [16].
Gene panel testing implies the identification of VUS 
[16, 21]. While the classification of VUS is a particular 
limitation and challenge in clinical applicability [22]; in a 
research context, these VUS can be further investigated 
to explore the genotype–phenotype correlation and to 
explain the genetic predisposition using the polygenic 
model. On the one hand, restrictive filters and in silico 
tools may be used to focus attention on a reduced list of 
mutations. On the other hand, the coexistence of several 
VUS in a number of patients would give us the opportu-
nity to explain the genetic causality using the polygenic 
model; the accumulative functional repercussions of 
several VUS may be conferring a significant risk. Other 
authors have associated co-occurring variants in DNA 
repair genes with an earlier onset of breast cancer, sug-
gesting a summation effect [23]. In our study, the global 
analysis revealed a complex variation landscape, where 
the number of variants with a possible functional impact 
Fig. 5 Association between the age of diagnoses of the index cases 
and tumor diversity in the respective families with the number of VUS 
identified in the sample. The upper plot shows how the condition 
of carrying 3 or more VUS could be determining early cancer onset. 
The lower plot represents the possible association of the categorical 
variable “tumor diversity in the family” defined as ‘yes’ when the 
pedigree harbored more than 3 tumor types. In particular, for the 
condition of carrying 4, 5 and 6 VUS, the tumor diversity in the 
pedigrees tends to increase
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per individual ranges from 1 to 6. Similarly to other anal-
yses [24], our data reveals a diversity in the number of 
variants detected in the different genes, but only 5 out of 
the 35 genes accumulated 50% of the VUS and PVs.
As the in silico analysis cannot resolve the clinical 
significance of a variant [25], we performed segrega-
tion studies on a limited number of families. The muta-
tions p.Asp95Asn in NBN and p.Lys425Arg in POLE 
segregated with both breast and ovarian cancer cases 
(Fig.  3a); the VUS in MSH6 p.Ser144Ile was identified 
in the two cases of breast cancer, one of them bilateral, 
in an HNPCC family (Fig.  3b). Although the variant 
had previously been identified in colon cancer cases 
[26], our analysis poses the possible contribution to 
the breast cancer phenotype. In a family that has colon, 
gastric and breast tumors, the variants p.Arg1436Gln 
in POLE and p.Pro2033Ser in ATR were identified in 
a breast cancer case and in her healthy brother of the 
index case. Variants affecting the functionality of ATR 
have been related with high risk for colon [27] and 
breast cancer [28]. Regarding mutatons in POLE, their 
contribution to colorectal cancer predisposition has 
been described [29]. Moreover, the p.Arg1436Gln vari-
ant in POLE presented a very high-CADD-score, 35. 
Therefore, taking into account the family history, it 
would be worth programming control endoscopies on 
the unaffected individual carrier. On the other hand, 
the identified VUS in this family, and the coexistence 
of colon, gastric and breast cancer cases, highlight the 
overlapping phenotypes between the different cancer 
phenotypes. This makes the targeted molecular test-
ing for single genes less favorable. Along these lines, 
expanding the spectrum of the studied genes by panel 
testing could bring unexpected genotype- cancer phe-
notype correlations.
As previously outlined, although family segregation 
studies can yield powerful data to reclassify a VUS, the 
small size of the family and the very limited number of 
recruited probans limited its potential [30]. Nevertheless, 
family co-segregation studies should be considered in the 
clinical routine to add more information to the genetic 
findings.
Fig. 6 Characterization of the c.1140 + 1G > C variant in BRIP1 at RNA level. The amplified PCR products were separated by a 2% agarose gel 
electrophoresis to detect the possible aberrant transcripts. Then, Sanger sequencing confirmed the different exon exclusions. The c.1140 + 1G > C 
variant in BRIP1 caused the skipping of exon 8, resulting in a product which is 222 nucleotides shorter than the full-length product (879 nucleotides)
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Although no significant genotype–phenotype asso-
ciations were found, some notable observations can be 
pointed out: the condition of carrying several VUS (espe-
cially more than 3) could be determining a younger diag-
nosis age in the cases and higher tumor diversity in their 
respective families. The analysis of large cohorts could 
allow us to establish these putative correlations.
We identified a new splicing BRIP1 variant, 
c.1140 + 1G > C. In Clinvar, there is a change of G > A in 
the same position, which classifies it as probably patho-
genic. It is known that variants affecting splicing donors 
or acceptor sites imply a loss of protein function [31] and 
this loss of function of BRIP1 has a pathogenic effect [32]. 
To get an insight into the potential effect of this variant, 
we performed a characterization at RNA level, confirm-
ing the fact that the nucleotide change, located in a splic-
ing donor site, caused a loss of exon 8.
Splicing alterations are normally the result of muta-
tions in the intronic flanking regions of the exon, but 
some exonic variants can affect mRNA processing, trig-
gering a functional alteration [33]. The mechanism is 
probably based on the alteration of potentiating sites 
(ESE) or splicing silencers (ESS) located in exonic regions 
[34]. Therefore, we explored the possible impact on the 
mRNA processing of two exonic variants predicted by 
HSF as possible splicing disruptors: the c.4076 + 4T > G 
variant in BLM and c.4473C > T in ATM. Neither the 
BLM mutation nor the ATM variant caused an aberrant 
RNA processing in the patient samples. Consequently, 
although the HSF algorithm has proven to be an efficient 
computational tool for predicting splicing alterations 
[35], whenever possible, an effort should be made to con-
firm the prediction at RNA patient level.
As previously remarked, the comprehensive gene panel 
was created to potentiate the detection of PVs. Intrigu-
ingly; some PVs are clustered in genes not directly related 
to the initial established phenotype according to fam-
ily history. In light of this, two major observations must 
be highlighted. First, the monoallelic PV in MUTYH 
c.1187G > A (p.Gly396Asp) was identified in four unre-
lated patients, a significantly high frequency when com-
pared to the data registered in ExAC (0.002). Given the 
fact that MUTYH is a recessive gene [36], MUTYH-
monallelic-PV could not explain the cancer phenotype; 
in contrast, several recent studies support the possible 
role of monoallelic mutations in MUTYH conferring risk 
[37] for colorectal, breast, gastric and endometrial cancer. 
In particular, the patients with the c.1187G > A variant 
in MUTYH were diagnosed with ovarian, endometrial, 
colorectal and gastric cancer, respectively, emphasis-
ing the possible contribution of PV in MUTYH to these 
cancer types, even heterozygous. Second, we identified 
two deleterious alterations in CHEK2, c.593-1G > T and 
p.Thr476Met, in two patients who developed breast can-
cer, a cancer type related to PV in this gene [38]. Intrigu-
ingly, the individual phenotype of both patients, breast 
cancer (in contrast to the familial phenotype, HNPCC), 
would be determining different preferences regarding the 
list of genes to screen. However, in this situation, there 
is an overlap of cancer types that may prompt us to take 
into account mutations in genes not exclusively corre-
lated with the familial syndrome. Conversely, the patient 
with the p.Pro747fs variant in MLH1 developed breast 
cancer at the age of 47. In principle, MLH1 would not be 
a candidate gene in breast cancer screening but, in this 
case, the fact that her family matched criteria for HNPCC 
allowed us to determine the PV in the patient.
Therefore, screening genes corresponding to other 
cancer phenotypes could give us the opportunity to 
define the testing genetic profile, especially when the 
family history gathers several cancer types, matching 
more than one hereditary cancer syndrome.
In the new era of targeted therapy in cancer, drug-
response records may serve as a reference for treatment 
selection. The fact that many of the proposed treatments 
are based on the synthetic lethality principle, in combi-
nation with the mutation profile, would lead to increased 
effectiveness and a decrease in side effects. Knowing that 
the transcendence of the genetic test results depends on 
its transference to clinical practice, we wanted to use 
the genetic information for treatment selection, making 
the application of the concept of personalized medicine 
plausible [39, 40]. According to other studies, the PV in 
ATM, BRCA2 and CHEK2 could be determining a PARP 
inhibitor sensitivity [41]. In addition, for ATM PV, a syn-
thetic lethality synergism has been described with DNA-
PKc and ATR inhibitors [42]. This information could be 
considered to design targeted therapy options in 6 of our 
patients.
Conclusion
On the basis of the preceding discussion, the imple-
mentation of gene-panels can improve the clinical 
management of affected families in a quick and cost-
effective method. Moreover, extending the analysis to 
other genes renders the opportunity to discover infre-
quent alterations and to provide a reliable molecular 
portrait of different cancers.
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